PURETHAL Mites 6,667 AU/ml

Phase 2Biologic

HHAL Allergy

PURETHAL Mites 6,667 AU/ml is one of 28 biologic programs targeting Allergic Rhinitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Sudafed

KKenvue Brands

Phase 3

3 2

Asmanex HFA

Sumitomo Pharma America, Inc.

Phase 3

1 3

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Phase 3

3 4

EMS Acarbose

EEMS

Phase 3

2 5

Asmanex

Novartis

Preclinical

12 6

HL151

HHanlim Pharm. Co., Ltd.

Phase 3

1 7

Veramyst

GSK

Preclinical

10 8

Singulair

AstraZeneca

Preclinical

5 9

Xolair

Roche

Preclinical

1 10

Bilaxten

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Allergic Rhinitis

NCT06920771

Clinical

Trials by Indication[1]

Allergic Rhinitis3 trials

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Completed·HHAL Allergy·Phase 2·NCT01438463·290 enrolled

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

Active, not recruiting·HHAL Allergy·Phase 3·NCT06920771·552 enrolled

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Completed·HHAL Allergy·Phase 2·NCT00973453·48 enrolled

Unspecified2 trials

PURETHAL Birch RUSH Study

Completed·HHAL Allergy·Phase 4·NCT01918956·120 enrolled

PURETHAL Grasses Rush Study

Completed·HHAL Allergy·Phase 4·NCT01059266·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PURETHAL Mites 6,667 AU/ml. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PURETHAL Mites 6,667 AU/ml compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PURETHAL Mites 6,667 AU/ml. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HAL Allergy company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: HHAL Allergy

PURETHAL Mites 6,667 AU/ml

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Allergic Rhinitis3 trials

Unspecified2 trials

References

Drug Info

Quick Facts

Related News